1. 参考文献

1. (1991). "Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group." BMJ **303**(6807): 893-896.

2. (2015) Japanese Intractable Diseases Information Center. "Number of medical care certificate holders by Specific Disease." from http://www.nanbyou.or.jp/entry/1356#p09

3. Avigan, M. I., et al. (1984). "Morphologic features of the liver in abetalipoproteinemia." Hepatology **4**(6): 1223-1226.

4. Baigent, C., et al. (2010). "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials." Lancet **376**(9753): 1670-1681.

5. Baigent, C., et al. (2005). "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins." Lancet **366**(9493): 1267-1278.

6. Bakillah, A., et al. (2000). "Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist." Biochemistry **39**(16): 4892-4899.

7. Beigel, R. and Y. Beigel (2009). "Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature." Journal of clinical apheresis **24**(6): 219-224.

8. Bambauer, R., et al. (2003). "Low-density lipoprotein apheresis: an overview." Ther Apher Dial **7**(4): 382-390.

9. Benayoun, L., et al. (2007). "Abetalipoproteinemia in Israel: evidence for a founder mutation in the Ashkenazi Jewish population and a contiguous gene deletion in an Arab patient." Molecular Genetics and Metabolism **90**(4): 453-457.

10. Benet, L. Z. and B. A. Hoener (2002). "Changes in plasma protein binding have little clinical relevance." Clin Pharmacol Ther **71**(3): 115-121.

11. Bilheimer, D. W. (1989). "Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia." Arteriosclerosis **9**(1 Suppl): I158-163.

12. Bogsrud, M. P., et al. (2011). "Apheresis in Homozygous Familial Hypercholesterolemia - Results of 35 Years of Follow-Up of All Norwegian Patients with Homozygous Familial Hypercholesterolemia [Abstract 10997]." Circulation Suppl. **124**(21 Suppl).

13. Boren, J., et al. (1993). "Influence of triacylglycerol biosynthesis rate on the assembly of apoB-100-containing lipoproteins in Hep G2 cells." Arterioscler Thromb **13**(12): 1743-1754.

14. Browning, J. D., et al. (2004). "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity." Hepatology **40**(6): 1387-1395.

15. Buchwald, H., et al. (1990). "Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases." Ann Surg **212**(3): 318-329; discussion 329-331.

16. Buchwald, H., et al. (1990). "Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)." N Engl J Med **323**(14): 946-955.

17. Buja, L. M., et al. (1979). "Cellular pathology of homozygous familial hypercholesterolemia." Am J Pathol **97**(2): 327-357.

18. Canner, P. L., et al. (1986). "Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin." J Am Coll Cardiol **8**(6): 1245-1255.

19. Chalasani, N. Y., Zobair; Lavine, Joel E.; Diehl, Anna Mae; Brunt, Elizabeth M.; Cusi, Kenneth; Charlton, Michael; Sanyal, Arun J. (2012). "The Diagnosis and Management of Non-Alcoholic Fatty-Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology." Gastroenterology **142**: 1592-1609.

20. Choi, S. S. and A. M. Diehl (2008). "Hepatic triglyceride synthesis and nonalcoholic fatty liver disease." Curr Opin Lipidol **19**(3): 295-300.

21. Cholestagel (2010). Summary of Product Characteristics.

22. Coker, M., et al. (2009). "Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia." Ther Apher Dial **13**(2): 121-128.

23. Crestor (2010). Package Insert.

24. Cuchel, M., et al. (2007). "Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia." N Engl J Med **356**(2): 148-156.

25. Cuchel, M., et al. (2013). "Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study." Lancet **381**(9860): 40-46.

26. Cuchel, M., et al. (2014). "Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society." Eur Heart J **35**(32): 2146-2157.

27. Deckelbaum, R. J., et al. (1977). "Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia." N Engl J Med **296**(9): 465-470.

28. Donner, M. G., et al. (1997). "Long-term follow-up of carotid atherosclerosis in patients with heterozygous familial hypercholesterolemia under LDL apheresis treatment." J Clin Apher **12**(4): 202-203.

29. Dressman, J. (2001). "The BCS: Where Do We Go from Here?" Pharmaceutical Technology: 68-76.

30. Evans, D. F. P., G.; Bramley, R.; Clark, A.G.; Dyson, T.J.; Hardcastle, J.D. (1988). "Measurement of gastrointestinal pH profiles in normal ambulant human subjects." Gut **29**: 1035-1041.

31. Forman, M. B., et al. (1982). "Treatment of homozygous familial hypercholesterolaemia with portacaval shunt." Atherosclerosis **41**(2-3): 349-361.

32. Fouchier, S. W., et al. (2001). "The molecular basis of familial hypercholesterolemia in The Netherlands." Hum Genet **109**(6): 602-615.

33. Gagne, C., et al. (2002). "Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia." Circulation **105**(21): 2469-2475.

34. Goldberg, R. J., et al. (1991). "Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience)." Am J Cardiol **67**(1): 55-58.

35. Goldstein, J. L., et al. (2001). Familial Hypercholesterolemia. New York, McGraw-Hill.

36. Goldstein, J. L., et al. (1973). "Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia." J Clin Invest **52**(7): 1544-1568.

37. Gordon, B. R., et al. (1998). "Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group." Am J Cardiol **81**(4): 407-411.

38. Grossman, M., et al. (1995). "A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia." Nat Med **1**(11): 1148-1154.

39. Grundy, S. M., et al. (2004). "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines." Circulation **110**(2): 227-239.

40. Hegele, R. A. (2001). "Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism." American journal of human genetics **69**(6): 1161-1177.

41. Hobbs, H. H., et al. (1992). "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia." Human mutation **1**(6): 445-466.

42. Hockley, T. and M. Gemmill (2007). European Cholesterol Guidelines Report, London School of Economics & Political Science.

43. Huang, M. and M. Deshpande (2004). "Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline." Expert Rev Anti Infect Ther **2**(3): 375-388.

44. Hudgins, L. C., et al. (2008). "Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia." The American journal of cardiology **102**(9): 1199-1204.

45. Hussain, M. M., et al. (2003). "Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly." Journal of lipid research **44**(1): 22-32.

46. Ibrahim, S. H., et al. (2011). "Mechanisms of lipotoxicity in NAFLD and clinical implications." J Pediatr Gastroenterol Nutr **53**(2): 131-140.

47. Jaeger, B. R., et al. (2002). "Long-term prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia." The Journal of pediatrics **141**(1): 125-128.

48. Jamil, H., et al. (1996). "An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells." Proc Natl Acad Sci U S A **93**(21): 11991-11995.

49. Joshipura, K. J., et al. (2001). "The effect of fruit and vegetable intake on risk for coronary heart disease." Ann Intern Med **134**(12): 1106-1114.

50. Kane, J. and R. Havel (2001). Disorders of the Biogenesis and Secretion of Lipoproteins Containing the B Apolipoproteins. New York, NY, McGraw-Hill.

51. Koga, N. (2005). "Overview on LDL-apheresis in cardiovascular diseases." Ther Apher Dial **9**(5): A39.

52. Kolansky, D. M., et al. (2008). "Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia." The American journal of cardiology **102**(11): 1438-1443.

53. Kroon, A. A., et al. (1996). "LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis." Circulation **93**(10): 1826-1835.

54. Kwiterovich, P. O., Jr., et al. (1974). "Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood." J Clin Invest **53**(5): 1237-1249.

55. Kynamro (2015). Package Insert.

56. LaRosa, J. C., et al. (1990). "The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association." Circulation **81**(5): 1721-1733.

57. Law, M. R. and N. J. Wald (2002). "Risk factor thresholds: their existence under scrutiny." BMJ **324**(7353): 1570-1576.

58. Lazo, M., et al. (2011). "Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study." BMJ **343**: d6891.

59. Liao, W., et al. (2003). "Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER." Journal of lipid research **44**(5): 978-985.

60. Lipid Research Clinics (1984a). "The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease." JAMA **251**(3): 351-364.

61. Lipid Research Clinics (1984b). "The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering." JAMA **251**(3): 365-374.

62. Lipitor (2009). Package Insert.

63. Lopez-Santamaria, M., et al. (2000). "Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass." J Pediatr Surg **35**(4): 630-633.

64. Marais, A. D. (2004). "Familial hypercholesterolaemia." Clin Biochem Rev **25**(1): 49-68.

65. Marais, A. D., et al. (2008). "A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia." Atherosclerosis **197**(1): 400-406.

66. Matsuzaki, M., et al. (2002). "Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART)." J Am Coll Cardiol **40**(2): 220-227.

67. Miniño, A. M., et al. (2011). "Deaths: final data for 2008." Natl Vital Stat Rep **59**(10): 1-126.

68. Moga, C. and C. Harstall (2004). Low density lipoprotein apheresis for the treatment of familial hypercholesterolemia. Health Technology Assessment, Alberta Heritage Foundation for Medical Research.

69. Moorjani, S., et al. (1993). "Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia." Lancet **341**(8856): 1303-1306.

70. Moss, A. J. (2006). "QTc prolongation and sudden cardiac death: the association is in the detail." J Am Coll Cardiol **47**(2): 368-369.

71. NCEP ATP III (2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)." JAMA **285**(19): 2486-2497.

72. Neaton, J. D. and D. Wentworth (1992). "Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group." Arch Intern Med **152**(1): 56-64.

73. Nishimura, S., et al. (1999). "Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS)." Atherosclerosis **144**(2): 409-417.

74. Nordestgaard, B. G., et al. (2013). "Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease - Consensus Statement of the European Atherosclerosis Society." Eur Heart J **34**(45): 3478-3490a.

75. Ogestrel [package insert]. Morristown, NJ: Watson Pharma, Inc.; 2007.

76. Ontario Health Technology Advisory Committee (2007). Low-Density Lipoprotein Apheresis. OHTAC Recommendation.

77. Palcoux, J. B., et al. (2008). "Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years." Ther Apher Dial **12**(3): 195-201.

78. Raal, F. J. and R. D. Santos (2012). "Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment." Atherosclerosis **223**(2): 262-268.

79. Raal, F. J., et al. (2010). "Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial." Lancet **375**(9719): 998-1006.

80. Rader, D. J., et al. (2003). "Monogenic hypercholesterolemia: new insights in pathogenesis and treatment." J Clin Invest **111**(12): 1795-1803.

81. Ratziu, V., et al. (2010). "A position statement on NAFLD/NASH based on the EASL 2009 special conference." J Hepatol **53**(2): 372-384.

82. Robinson, J. G., et al. (2005). "Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis." J Am Coll Cardiol **46**(10): 1855-1862.

83. Sachais, B. S., et al. (2005). "Long-term effects of LDL apheresis in patients with severe hypercholesterolemia." J Clin Apher **20**(4): 252-255.

84. Schmidt, H. H., et al. (2008). "Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL-receptor gene mutation." Clin Transplant **22**(2): 180-184.

85. Sjouke, B., et al. (2014). "Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome." Eur Heart J **36**(9): 560-565.

86. Sniderman, A. D., et al. (2011). "A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk." Circ Cardiovasc Qual Outcomes **4**(3): 337-345.

87. Stein, E. A. (2009). "Other therapies for reducing low-density lipoprotein cholesterol: medications in development." Endocrinology and metabolism clinics of North America **38**(1): 99-119.

88. Straus, S. M., et al. (2006). "Prolonged QTc interval and risk of sudden cardiac death in a population of older adults." J Am Coll Cardiol **47**(2): 362-367.

89. Suzuki, M., et al. (2001). "Implications from and for food cultures for cardiovascular disease: longevity." Asia Pac J Clin Nutr **10**(2): 165-171.Szczepaniak, L. S., et al. (2005). "Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population." American journal of physiology. Endocrinology and metabolism **288**(2): E462-468.

90. Teramoto, T., et al. (2013). "Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version." J Atheroscler Thromb **20**(6): 517-523.

91. Thompsen, J. and P. D. Thompson (2006). "A systematic review of LDL apheresis in the treatment of cardiovascular disease." Atherosclerosis **189**(1): 31-38.

92. Thompson, G. R., et al. (2010). "Efficacy criteria and cholesterol targets for LDL apheresis." Atherosclerosis **208**(2): 317-321.

93. Thompson, G. R., et al. (1985). "Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange." Br Med J (Clin Res Ed) **291**(6510): 1671-1673.

94. Tonstad, S. and G. R. Thompson (2004). "Management of Hyperlipidemia in the Pediatric Population." Curr Treat Options Cardiovasc Med **6**(5): 431-437.

95. Uauy, R., et al. (1992). "Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis." J Pediatr **120**(6): 892-898.

96. Watkins, P. B., et al. (2008). "Using controlled clinical trials to learn more about acute drug-induced liver injury." Hepatology **48**(5): 1680-1689.

97. Welchol (2011). Package Insert.

98. Wetterau, J. R., et al. (1998). "An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits." Science **282**(5389): 751-754.

99. Wetterau, J. R., et al. (1997). "Microsomal triglyceride transfer protein." Biochim Biophys Acta **1345**(2): 136-150.

100. Williams, R. R., et al. (1993). "Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics." Am J Cardiol **72**(2): 171-176.

101. Wilson, P. W., et al. (1980). "Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols." Am J Cardiol **46**(4): 649-654.

102. Winters, J. L. (2012). "Low-density lipoprotein apheresis: principles and indications." Semin Dial **25**(2): 145-151.

103. Zamel, R., et al. (2008). "Abetalipoproteinemia: two case reports and literature review." Orphanet journal of rare diseases **3**: 19.

104. Zetia (2009). Package Insert.

105. Ziajka, P. (2005). "Role of low-density lipoprotein apheresis." Am J Cardiol **96**(4A): 67E-69E.

106. Zimmerman, H. (1978). Drug Induced Liver Disease. Hepatotoxicity, The Adverse Effects of Drugs and Other Chemicals on the Liver. New York, Appleton-Century-Crofts**:** 351-353.

107. Zocor (2010). Package Insert.